Cardiac Myosin Activators in Systolic Heart Failure: More Friend Than Foe?

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2016 Aug 30

PMID 27568794

Citations 3

Authors

Danyaal S Moin

Julia Sackheim

Carine E Hamo

Javed Butler

Affiliations

Soon will be listed here.

Abstract

Despite the rising prevalence of HF, new evidence-based novel therapies for patients with worsening HF remain lacking, e.g., safe inotropic therapies. Traditional inotropes increase contractility by altering intracellular calcium flux, a pathway that may be responsible for the multitude of adverse effects associated with current options. Omecamtiv mecarbil, a direct myosin activator, increases contractility through a distinct pathway by increasing the proportion of myosin heads that are bound to actin in a high-affinity state. Phase II clinical trials in patients with chronic HF with this agent seem promising. A phase III trial investigating this therapy has not yet been pursued to date.

Citing Articles

Model order reduction for left ventricular mechanics via congruency training.

Di Achille P, Parikh J, Khamzin S, Solovyova O, Kozloski J, Gurev V PLoS One. 2020; 15(1):e0219876.

PMID: 31905197 PMC: 6944464. DOI: 10.1371/journal.pone.0219876.

Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.

El-Oumeiri B, Mc Entee K, Annoni F, Herpain A, Vanden Eynden F, Jespers P BMC Cardiovasc Disord. 2018; 18(1):99.

PMID: 29783950 PMC: 5963065. DOI: 10.1186/s12872-018-0831-3.

Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.

Brown D, Perry J, Allen M, Sabbah H, Stauffer B, Shaikh S Nat Rev Cardiol. 2016; 14(4):238-250.

PMID: 28004807 PMC: 5350035. DOI: 10.1038/nrcardio.2016.203.

References

Hessel M, Atsma D, van der Valk E, Bax W, Schalij M, van der Laarse A . Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch. 2007; 455(6):979-86. PMC: 2226063. DOI: 10.1007/s00424-007-0354-8. View

Teerlink J, Felker G, McMurray J, Ponikowski P, Metra M, Filippatos G . Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016; 67(12):1444-1455. DOI: 10.1016/j.jacc.2016.01.031. View

Teerlink J, Clarke C, Saikali K, Lee J, Chen M, Escandon R . Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011; 378(9792):667-75. DOI: 10.1016/S0140-6736(11)61219-1. View

Chen J, Normand S, Wang Y, Krumholz H . National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011; 306(15):1669-78. PMC: 3688069. DOI: 10.1001/jama.2011.1474. View

Elis A, Bental T, Kimchi O, Ravid M, Lishner M . Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther. 1998; 63(6):682-5. DOI: 10.1016/S0009-9236(98)90092-3. View

Shen Y, Malik F, Zhao X, Depre C, Dhar S, Abarzua P . Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010; 3(4):522-7. DOI: 10.1161/CIRCHEARTFAILURE.109.930321. View

Kojima S, Wu S, Parmley W, Wikman-Coffelt J . Relationship between intracellular calcium and oxygen consumption: effects of perfusion pressure, extracellular calcium, dobutamine, and nifedipine. Am Heart J. 1994; 127(2):386-91. DOI: 10.1016/0002-8703(94)90129-5. View

Schwartz P, Piper H, Spahr R, Spieckermann P . Ultrastructure of cultured adult myocardial cells during anoxia and reoxygenation. Am J Pathol. 1984; 115(3):349-61. PMC: 1900509. View

Colucci W . Cardiovascular effects of milrinone. Am Heart J. 1991; 121(6 Pt 2):1945-7. DOI: 10.1016/0002-8703(91)90829-7. View

10.

Cuffe M, Califf R, Adams Jr K, Benza R, Bourge R, Colucci W . Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287(12):1541-7. DOI: 10.1001/jama.287.12.1541. View

11.

Gao W, Atar D, Liu Y, Perez N, Murphy A, Marban E . Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res. 1997; 80(3):393-9. View

12.

Cleland J, Teerlink J, Senior R, Nifontov E, Mc Murray J, Lang C . The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011; 378(9792):676-83. DOI: 10.1016/S0140-6736(11)61126-4. View

13.

De Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A . Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J. 2012; 163(5):821-8. DOI: 10.1016/j.ahj.2012.03.004. View

14.

Stevenson L . Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation. 2003; 108(4):492-7. DOI: 10.1161/01.CIR.0000078349.43742.8A. View

15.

Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier L, Just H . Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998; 98(20):2141-7. DOI: 10.1161/01.cir.98.20.2141. View

16.

Wang T . Significance of circulating troponins in heart failure: if these walls could talk. Circulation. 2007; 116(11):1217-20. DOI: 10.1161/CIRCULATIONAHA.107.721845. View

17.

Bader F, Gilbert E, Mehta N, Bristow M . Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010; 16(6):265-70. DOI: 10.1111/j.1751-7133.2010.00185.x. View

18.

Ito M, Tanaka T, Saitoh M, Masuoka H, Nakano T, Hidaka H . Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine. Biochem Pharmacol. 1988; 37(10):2041-4. DOI: 10.1016/0006-2952(88)90554-0. View

19.

Roger V, Weston S, Redfield M, Hellermann-Homan J, Killian J, Yawn B . Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292(3):344-50. DOI: 10.1001/jama.292.3.344. View

20.

Malik F, Hartman J, Elias K, Morgan B, Rodriguez H, Brejc K . Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011; 331(6023):1439-43. PMC: 4090309. DOI: 10.1126/science.1200113. View